FDA approves first targeted therapy for metastatic bladder cancer
The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Genetics | Pharmaceuticals